

CURRICULUM VITAE**INFORMAZIONI PERSONALI**

COGNOME E NOME

TAGLIABUE ELDA

DATA DI NASCITA

23 SETTEMBRE 1955

AMMINISTRAZIONE

FONDAZIONE IRCCS – ISTITUTO NAZIONALE DEI TUMORI

INCARICO E STRUTTURA

Responsabile, Unità Operativa 'Bersagli Molecolari' – Dipartimento di Oncologia Sperimentale e Medicina Molecolare

NUMERO TELEFONICO UFFICIO

+39/02/23903013

FAX UFFICIO

+39/02/23902692

E-MAIL ISTITUZIONALE

elda.tagliabue@istitutotumori.mi.it

**TITOLI DI STUDIO E PROFESSIONALI ED
ESPERIENZE
LAVORATIVE**

TITOLO DI STUDIO

Laurea in Scienze Biologiche conseguita nel 1978 presso l'università Statale di Milano

ALTRI TITOLI DI STUDIO E
PROFESSIONALI

Diploma di Maturità Classica conseguito nel 1974

ESPERIENZE PROFESSIONALI

01/10/1979-31/12/1982 Borsista presso la Divisione di Oncologia Sperimentale A;
 01/01/1983-31/05/1985 Ricercatore Associato presso la Divisione di Oncologia Sperimentale E;
 01/06/1985- 31/12/1990 Ricercatore Associato Incaricato presso la Divisione di Oncologia Sperimentale E;
 01/01/1991-31/12/1997 Membro dello Staff della Divisione di Oncologia Sperimentale E;
 01/01/1998-31/12/2008 Membro dello Staff dell'Unità Operativa Bersagli Molecolari;
 01/01/2009 a tutt'oggi Responsabile dell'Unità Operativa Bersagli Molecolari – Dipartimento di Oncologia Sperimentale e Medicina Molecolare.

CAPACITÀ LINGUISTICHE

LINGUA	LIVELLO PARLATO	LIVELLO SCRITTO
INGLESE	FLUENTE	FLUENTE

CAPACITÀ NELL'USO DELLE TECNOLOGIE

- Produzione e caratterizzazione di anticorpi monoclonali murini diretti contro antigeni associati a carcinomi umani. Studi in vitro sulle interazioni di membrana fra anticorpi monoclonali e gli antigeni da essi riconosciuti
- Risposta e ottimizzazione dell'uso di farmaci convenzionali e bersaglio specifici nella patologia mammaria e specialmente nei tumori HER2-positivi; studio del loro meccanismo d'azione e delle combinazioni terapeutiche possibili
- Studi sul ruolo svolto dalla oncoproteina HER2 nella progressione del carcinoma mammario. In particolare definizione del meccanismo di segnalazione di questo recettore nelle condizioni fisiologiche e in quelle patologiche, con riferimento particolare alle cellule di carcinoma della mammella.
- Studio del ruolo della matrice extracellulare nella progressione del carcinoma della mammella e nella risposta ai farmaci convenzionali e bersaglio specifici

ALTRO

PARTECIPAZIONE E RELAZIONI A
 CONVEGNI, SEMINARI, PUBBLICAZIONI,
 COLLABORAZIONI A RIVISTE, ECC., ED
 OGNI ALTRA INFORMAZIONE CHE SI

Autore di 167 pubblicazioni scientifiche in extenso su vari aspetti dell'oncologia sperimentale e translazionale.
 Project Leader di un progetto AIRC triennale riguardante l'ottimizzazione delle terapie mirate contro l'oncoproteina HER2.
 Co-investigatore in altri progetti finanziati da AIRC e dal Ministero della Salute.
 Membro di Società Scientifiche tra cui: American Association for Cancer Research, International

Bibliografia degli ultimi 5 anni

1. Rossini A, Zanobbio L, Sfondrini L, Cavalleri A, Secreto G, Morelli D, et al. Influence of fatty acid-free diet on mammary tumor development and growth rate in HER-2/neu transgenic mice. *J Cell Physiol* 2013;228:242-9.
2. Triulzi T, Tagliabue E, Balsari A, Casalini P. FOXP3 expression in tumor cells and implications for cancer progression. *J Cell Physiol* 2013;228:30-5.
3. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, et al. Potential role of HER2-overexpressing exosomes in countering Trastuzumab-based therapy. *J Cell Physiol* 2012;227:658-67.
4. Giordano A, Tagliabue E, Pupa SM. Promise and failure of targeted therapy in breast cancer. *Front Biosci (Schol Ed)* 2012;4:356-74.
5. Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Tortoreto M, et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. *Mol Oncol* 2012;6:458-72.
6. Ripamonti F, Albano L, Rossini A, Borrelli S, Fabris S, Mantovani R, et al. EGFR through STAT3 is a player in deltaNp63a expression and together sustain tumor-initiating cell proliferation in squamous cell carcinomas. *J Cell Physiol* 2012;[Epub ahead of print].
7. Rossini A, Giussani M, Giacomini A, Guarnotta C, Tagliabue E, Balsari A. Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34+ cells in a xenograft model. *Breast Cancer Res Treat* 2012;[Epub ahead of print].
8. Rumio C, Sommariva M, Sfondrini L, Palazzo M, Morelli D, Viganò L, et al. Induction of Paneth cell degranulation by orally administered Toll-like receptor ligands. *J Cell Physiol* 2012;227:1107-13.
9. Sommariva M, De Cecco L, Tagliabue E, Balsari A. Modulation of DNA repair genes induced by TLR9 agonists. A strategy to eliminate "altered" cells? *Oncolmunology* 2012;1:258-9.
10. Tagliabue E, Campiglio M, Pupa SM, Ménard S, Balsari A. Activity and resistance mechanisms of trastuzumab in different clinical settings. *Cancer Treat Rev* 2012;38:212-7.
11. Tagliabue E, Campiglio M, Balsari A, Ménard S. Prediction of response to trastuzumab in ErbB2-positive human xenograft model. *J Nucl Med* 2012;53:1654-5.
12. Triulzi T, Casalini P, Sandri M, Callari M, Iacono M, Colombo MP, et al. Combined tumor and stromal features represent a key force for breast carcinoma progression. *PLoS ONE* 2012;accepted with minor revision.
13. Allemani C, Berrino F, Krogh V, Sieri S, Pupa SM, Tagliabue E, et al. Do pre-diagnostic drinking habits influence breast cancer survival? *Tumori* 2011;97:142-8.
14. Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, et al. International expert consensus on primary systemic therapy in the management of early breast cancer. Highlights of the third symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy, 2010. *J Natl Cancer Inst Monogr* 2011;2011:147-51.
15. Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello RA, De Matteis A, et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. *Breast Cancer Res Treat* 2011;128:147-54.
16. Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E. Ch.19 - Current and future developments in cancer therapy research: miRNAs as new promising targets or tools. Biotarget of cancer in current clinical practice. Springer monograph; 2011.
17. Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E. Breast cancer and microRNAs: therapeutic impact. *Breast* 2011;20 suppl 3:S63-S70.
18. Licitra L, Perrone E, Tamborini E, Bertola L, Ghirelli C, Negri M, et al. Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. *Ann Oncol* 2011;22:1886-93.
19. Marchini C, Gabrielli F, Iezzi M, Zanobi S, Montani M, Pietrella L, et al. The human splice variant delta16HER2 induces rapid tumor onset in a reporter transgenic mouse. *PLoS ONE* 2011;6:e18727.
20. Pupa SM, Campiglio M, Rossini A, Orlandi R, Ciravolo V, Amici A, et al. Role of Δ16HER2 splice variant in breast tumor progression and response to HER2-targeted therapy. In: Williams SI, Rogers CE, editors. *HER2 and Cancer: Mechanism, Testing and Targeted Therapy*. Nova Science Publishers, Inc.; 2011. p. 201-9.
21. Sasso M, Bianchi F, Ciravolo V, Tagliabue E, Campiglio M. HER2 splice variants and their relevance in breast cancer. *J Nucl Acids Invest* 2011;2:e9.
22. Sommariva M, De Cecco L, De Cesare M, Sfondrini L, Ménard S, Melani C, et al. TLR9-agonists oppositely modulate DNA-repair genes in tumor versus immune cells and enhance chemotherapy effects. *Cancer Res* 2011;71:6382-90.
23. Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S. The HER2 world: better treatment selection for better outcome. *J Natl Cancer Inst Monogr* 2011;2011:82-5.
24. De Cesare M, Sfondrini L, Campiglio M, Sommariva M, Bianchi F, Perego P, van Rooijen N, Supino R, et al. Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. *J Immunother* 2010;33:8-15.
25. Feng W, Orlandi R, Zhao N, Carcangiu M-L, Tagliabue E, Xu J, Bast RC, Jr., Yu Y. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. *BMC Cancer* 2010;10:378.
26. Gasparini P, Bertolini G, Binda M, Magnifico A, Albano L, Tortoreto M, Pratesi G, Facchinetti F, et al. Molecular cytogenetic characterization of stem-like cancer cells isolated from established cell lines. *Cancer Lett* 2010 Apr 30;296:206-15.
27. Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, et al. Role of soluble HER2 extracellular domain in HER2-mediated tumor growth and in response to Trastuzumab. *J Cell Physiol* 2010;225:256-65.

28. Lucci MA, Orlandi R, Triulzi T, Tagliabue E, Balsari A, Villa-Moruzzi E. Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. *Cell Oncol* 2010 Apr 22;32:361-72.
29. Podo F, Buydens LM, Degani H, Hihorst R, Klipp E, Gribbestad IS, Van HS, van Laarhoven WM, et al. Triple-negative breast cancer: Present challenges and new perspectives. *Mol Oncol* 2010 Apr 24;4:209-29.
30. Rossini A, Zanobbio L, Palazzo M, Sfondrini L, Morelli D, Tagliabue E, Balsari A, Rumio C. Influence of lignans depletion on murine mammary gland morphology. *Nutr Cancer* 2010;62:237-42.
31. Tagliabue E, Balsari A, Campiglio M, Pupa SM. HER2 as a target for breast cancer therapy. *Expert Opin Biol Ther* 2010;10:711-24.
32. Iorio MV, Casalini P, Piovano C, Di Leva G, Merlo A, Triulzi T, Ménard S, Croce CM, et al. microRNA-205 regulates HER3 in human breast cancer. *Cancer Res* 2009 Mar 15;69:2195-200.
33. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi G, Fontanella E, et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to Trastuzumab. *Clin Cancer Res* 2009;15:2010-21.
34. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Ménard S, Tagliabue E, Balsari A. FOXP3 expression and overall patient survival in breast cancer. *J Clin Oncol* 2009;27:1746-52.
35. Bergamaschi A, Tagliabue E, Sorlie T, Naume B, Triulzi T, Orlandi R, Tammi R, Giercksky H, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. *J Pathol* 2008;214:357-67.
36. Bossi P, Locati LD, Tagliabue E, Licitra L. Folate in head and neck squamous cell cancer chemoprevention: purposely left out? (letter). *J Clin Oncol* 2008;26:3463.
37. Casalini P, Carcangiu ML, Tammi R, Auvinen P, Kosma VM, Valagussa P, Greco M, Balsari A, et al. Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact. *Clin Cancer Res* 2008 Jan 1;14:25-31.
38. Iorio MV, Casalini P, Tagliabue E, Menard S, Croce CM. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. *Eur J Cancer* 2008 Nov 18;44:2753-9.
39. Merlo A, Tagliabue E, Ménard S, Balsari A. Matured human monocyte-derived dendritic cells (MoDCs) induce expansion of CD4(+)CD25(+)FOXP3(+) T cells lacking regulatory properties. *Immunol Lett* 2008 Feb 7;117:106-13.
40. Ménard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, et al. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. *Ann Oncol* 2008 Jun 9;19:1706-12.
41. Pratesi G, Petrangolini G, Tortoreto M, Addis A, Zunino F, Calcaterra C, Merlo A, Tagliabue E, et al. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. *J Immunother* 2008;31:537-44.
42. Bianchi F, Tagliabue E, Ménard S, Campiglio M. Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections. *Cell Cycle* 2007 Mar;6:643-6.
43. Bossi P, Liberatoscioli C, Bergamini C, Locati L, Fava S, Rinaldi G, Orlandi E, Olmi P, et al. Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients. *Ann Oncol* 2007 Mar;18:601-2.
44. Casalini P, Iorio MV, Bero V, Bergamaschi A, Borresen Dale AL, Gasparini P, Orlandi R, Casati B, et al. Relationship between p53 and p27 expression following HER2 signaling. *Breast* 2007 Jun 27;16:597-605.
45. Castiglioni F, Terenziani M, Carcangiu ML, Miliano R, Aiello P, Bertola L, Triulzi T, Gasparini P, et al. Radiation effects on development of HER2-positive breast carcinomas. *Clin Cancer Res* 2007 Jan 1;13:46-51.
46. Magnifico A, Albano L, Campaner S, Campiglio M, Pilotti S, Ménard S, Tagliabue E. Protein Kinase C α determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. *Cancer Res* 2007 Jun 1;67:5308-17.
47. Pupa SM, Giuffrè S, Castiglioni F, Bertola L, Cantu M, Bongarzone I, Baldassari P, Mortarini R, et al. Regulation of breast cancer response to chemotherapy by fibulin-1. *Cancer Res* 2007 Jan 5;67:4271-7.
48. Sant M, Allemanni C, Sieri S, Krogh V, Ménard S, Tagliabue E, Nardini E, Micheli A, et al. Salad vegetables dietary pattern protects against HER-2-positive breast cancer: A prospective Italian study. *Int J Cancer* 2007 Apr 23;121:911-4.
49. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Santo Silva L, Tagliabue E, Ménard S, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity (ADCC) in patients under trastuzumab therapy for primary operable breast cancer overexpressing HER2. *Cancer Res* 2007;67:11991-9.
50. Bianchi F, Magnifico A, Olgiati C, Zanesi N, Pekarsky Y, Tagliabue E, Croce CM, Ménard S, et al. FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells. *Proc Natl Acad Sci U S A* 2006 Dec 1;103:18981-6.
51. Campiglio M, Bianchi F, Andriani F, Sozzi G, Tagliabue E, Ménard S, Roz L. Diadenosines as FHIT-ness instructors. *J Cell Physiol* 2006 Mar 17;208:274-81.
52. Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S. Role of exon-16-deleted HER2 in breast carcinomas. *Endocr Relat Cancer* 2006;13:221-32.
53. Rossini A, Rumio C, Sfondrini L, Tagliabue E, Morelli D, Miceli R, Mariani L, Palazzo M, et al. Influence of antibiotic treatment on breast carcinoma development in proto-neu transgenic mice. *Cancer Res* 2006;66:6219-24.
54. Sfondrini L, Rossini A, Besusso D, Merlo A, Tagliabue E, Ménard S, Balsari A. Anti-tumor activity of the Toll-like receptor-5 ligand flagellin in mouse models of cancer. *J Immunol* 2006;176:6624-30.
55. Tagliabue E, Agresti R, Casalini P, Mariani L, Carcangiu ML, Balsari A, Veronesi U, Ménard S. Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. *Eur J Cancer* 2006 May;42:1057-61.
56. Bero V, Porrini D, Castiglioni F, Campiglio M, Casalini P, Pupa SM, Balsari A, Ménard S, et al. The 67-kDa laminin receptor increases tumor aggressiveness by remodeling laminin-1. *Endocr Relat Cancer* 2005;12:393-406.
57. Kringen P, Bergamaschi A, Due EU, Wang Y, Tagliabue E, Nesland JM, Nehman A, Tonisson N, et al. Evaluation of arrayed primer extension for TP53 mutation detection in breast and ovarian carcinomas. *Biotechniques* 2005 Nov;39:755-61.
58. Ménard S, Pupa SM, Campiglio M, Balsari A, Fagnoni F, Costa A, Tagliabue E. Apoptosis induction by trastuzumab: possible role of the core biopsy intervention. *J Clin Oncol* 2005;23:7238-40.

59. Pupa SM, Tagliabue E, Ménard S, Anichini A. HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine. *J Cell Physiol* 2005 May 10;205:10-8.